Skip to main content

Table 1 Baseline characteristics

From: A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome

Characteristics Placebo
(n = 3)
0.06 mg/kg ALT-836
(n = 5)
0.08 mg/kg ALT-836
(n = 5)
0.10 mg/kg ALT-836
(n = 5)
Age, yr 49.7 ± 24.3 40.4 ± 18.2 54.0 ± 16.9 54.6 ± 13.7
Male, n (%) 1 (33.3) 1 (20.0) 2 (40.0) 0 (0.0)
Baseline APACHE II Score 22.7 ± 14.2 20.2 ± 5.5 20.0 ± 3.1 19.2 ± 5.1
Baseline respiratory variables     
   PO2/FIO2 226 ± 51 205 ± 65 221 ± 64 200 ± 48
   Respiratory rate, bpm 28.7 ± 4.2 20.3 ± 6.9 20.60 ± 3.3a 19.8 ± 7.2
   pH 7.34 ± 0.09 7.35 ± 0.07 7.44 ± 0.04 7.39 ± 0.06
   PEEP, cm H2O 10.0 ± 5.0 10.3 ± 5.6 10.4 ± 6.2 9.2 ± 4.1
Baseline coagulation & hematology variables     
   Prothrombin time, sec 17.0 ± 2.4 12.1 ± 1.5 14.8 ± 1.9 13.9 ± 0.3
   aPTT, sec 32.9 ± 0.3 29.1 ± 2.5 31.1 ± 1.8 29.2 ± 1.7
   Platelets, 106/ml 238 ± 115 256 ± 105 357 ± 309 244 ± 43
   Hemoglobin, g/dl 10.7 ± 0.3 9.5 ± 1.2 10.0 ± 1.4 10.0 ± 1.8
  1. APACHE II, Acute Physiology and Chronic Health Evaluation; PEEP, Positive end-expiratory pressure; aPTT, activated partial thromboplastin time
  2. Values are means ± SD unless otherwise noted
  3. a P < 0.05 compared to placebo group